RxDoctor Payments Data

Harold Pierce, MD

Urology · Laramie, WYNPI 1639262595

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Neotract Inc. at 40.1% of the total. Reporting peaked in 2019 at $676 and has fallen 90.2% since, to $66 in 2024.

$1,636in general payments, 2019–2025

Across 36 payments — averaging $45.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$657
  • Coloplast$423
  • Astellas Pharma US Inc$213
  • Sumitomo Pharma America, Inc.$104
  • Myovant Sciences Inc.$68
  • Boston Scientific$39
  • plus $132 from 7 others

What the payments were for

  • Travel & lodging$68842%
  • Food & beverage$74546%
  • Education$20312%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$138,304
Medicare patients
451
Services billed
2,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron84$76,065
Tamsulosin Hcl525$11,212
GemtesaVibegron11$8,448
Finasteride342$6,733
Potassium Citrate ErPotassium Citrate37$5,192
Fesoterodine Fumarate ErFesoterodine Fumarate18$4,376
Oxybutynin Chloride ErOxybutynin Chloride64$1,849
Alfuzosin Hcl ErAlfuzosin Hcl45$1,601
Dutasteride23$1,171
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst67$1,168
Solifenacin Succinate16$562
Bicalutamide18$543
Doxazosin Mesylate21$377
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim104$329
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$213$76,06584 claims
Sumitomo Pharma America, Inc.Gemtesa$104$8,44811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other urology in Laramie

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →